DOCSLIB.ORG

Datasheet PB1029 Anti-AEBP2 Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Datasheet PB1029 Anti-AEBP2 Antibody Product datasheet Anti-AEBP2 Antibody Catalog Number: PB1029 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-AEBP2 Antibody Gene Name AEBP2 Source Rabbit IgG Species Reactivity human,mouse,rat Tested Application WB,IHC-P,ICC/IF,FCM Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen E.coli-derived human AEBP2 recombinant protein (Position: K424-Q517). Human AEBP2 shares 98.8% amino acid (aa) sequence identity with mouse AEBP2. Purification Immunogen affinity purified. Observed MW 54KD Dilution Ratios Western blot: 1:500-2000 Immunohistochemistry(Paraffin-embedded Section): 1:50-400 Immunocytochemistry/Immunofluorescence (ICC/IF): 1:50-400 Flow cytometry (FCM): 1-3μg/1x106 cells Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information Adipocyte Enhancer-Binding Protein is a zinc finger protein that in humans is encoded by the evolutionarily well-conserved gene AEBP2. This gene is mapped to 12p12.3. AEBP2 is a DNA-binding transcriptional repressor. It may regulate the migration and development of the neural crest cells through the PRC2-mediated epigenetic mechanism and is most likely a targeting protein for the mammalian PRC2 complex. Reference Anti-AEBP2 Antibody被引用在0文献中。 暂无引用 FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 1 Product datasheet Anti-AEBP2 Antibody Catalog Number: PB1029 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Selected Validation Data Figure 1. Western blot Figure 2. IHC analysis of analysis of AEBP2 using AEBP2 using anti- AEBP2 anti-AEBP2 antibody antibody (PB1029).AEBP2 (PB1029). Electrophoresis was detected in paraffin- was performed on a embedded section of 5-20% SDS-PAGE gel at human lung cancer 70V (Stacking gel) / 90V tissues. Heat mediated (Resolving gel) for 2-3 antigen retrieval was hours. The sample well of performed in citrate each lane was loaded buffer (pH6, epitope with 50ug of sample retrieval solution) for 20 under reducing mins. The tissue section conditions. Lane 1: HL-60 was blocked with 10% whole cell lysates.After goat serum. The tissue Electrophoresis, proteins section was then were transferred to a incubated with 1μg/ml Nitrocellulose membrane rabbit anti- AEBP2 at 150mA for 50-90 Antibody (PB1029) minutes. Blocked the overnight at 4°C. membrane with 5% Non- Biotinylated goat anti- fat Milk/ TBS for 1.5 hour rabbit IgG was used as at RT. The membrane was secondary antibody and incubated with rabbit anti- incubated for 30 minutes AEBP2 antigen affinity at 37°C. The tissue purified polyclonal section was developed antibody (Catalog # using Strepavidin-Biotin- PB1029) at 0.5 μg/mL Complex (SABC)(Catalog overnight at 4°C, then # SA1022) with DAB as washed with the chromogen. TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti- rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for AEBP2 at approximately 54KD. The expected band size for AEBP2 is at 54KD. FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 2 Product datasheet Anti-AEBP2 Antibody Catalog Number: PB1029 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Figure 3. IHC analysis of Figure 4. IHC analysis of AEBP2 using anti- AEBP2 AEBP2 using anti- AEBP2 antibody (PB1029).AEBP2 antibody (PB1029).AEBP2 was detected in paraffin- was detected in paraffin- embedded section of embedded section of human mammary cancer human placenta tissues. tissues. Heat mediated Heat mediated antigen antigen retrieval was retrieval was performed performed in citrate in citrate buffer (pH6, buffer (pH6, epitope epitope retrieval solution) retrieval solution) for 20 for 20 mins. The tissue mins. The tissue section section was blocked with was blocked with 10% 10% goat serum. The goat serum. The tissue tissue section was then section was then incubated with 1μg/ml incubated with 1μg/ml rabbit anti- AEBP2 rabbit anti- AEBP2 Antibody (PB1029) Antibody (PB1029) overnight at 4°C. overnight at 4°C. Biotinylated goat anti- Biotinylated goat anti- rabbit IgG was used as rabbit IgG was used as secondary antibody and secondary antibody and incubated for 30 minutes incubated for 30 minutes at 37°C. The tissue at 37°C. The tissue section was developed section was developed using Strepavidin-Biotin- using Strepavidin-Biotin- Complex (SABC)(Catalog Complex (SABC)(Catalog # SA1022) with DAB as # SA1022) with DAB as the chromogen. the chromogen. FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 3 Powered by TCPDF (www.tcpdf.org).
Load more

Recommended publications
  • Polycomb Repressor Complex 2 Function in Breast Cancer (Review)
    INTERNATIONAL JOURNAL OF ONCOLOGY 57: 1085-1094, 2020 Polycomb repressor complex 2 function in breast cancer (Review) COURTNEY J. MARTIN and ROGER A. MOOREHEAD Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G2W1, Canada Received July 10, 2020; Accepted September 7, 2020 DOI: 10.3892/ijo.2020.5122 Abstract. Epigenetic modifications are important contributors 1. Introduction to the regulation of genes within the chromatin. The poly- comb repressive complex 2 (PRC2) is a multi‑subunit protein Epigenetic modifications, including DNA methylation complex that is involved in silencing gene expression through and histone modifications, play an important role in gene the trimethylation of lysine 27 at histone 3 (H3K27me3). The regulation. The dysregulation of these modifications can dysregulation of this modification has been associated with result in pathogenicity, including tumorigenicity. Research tumorigenicity through the increased repression of tumour has indicated an important influence of the trimethylation suppressor genes via condensing DNA to reduce access to the modification at lysine 27 on histone H3 (H3K27me3) within transcription start site (TSS) within tumor suppressor gene chromatin. This methylation is involved in the repression promoters. In the present review, the core proteins of PRC2, as of multiple genes within the genome by condensing DNA well as key accessory proteins, will be described. In addition, to reduce access to the transcription start site (TSS) within mechanisms controlling the recruitment of the PRC2 complex gene promoter sequences (1). The recruitment of H1.2, an H1 to H3K27 will be outlined. Finally, literature identifying the histone subtype, by the H3K27me3 modification has been a role of PRC2 in breast cancer proliferation, apoptosis and suggested as a mechanism for mediating this compaction (1).
    [Show full text]
  • Ablation of Ezh2 in Neural Crest Cells Leads to Hirschsprung's Disease-Like Phenotype in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/265868; this version posted February 15, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Ablation of Ezh2 in neural crest cells leads to Hirschsprung’s disease-like phenotype in mice Hana Kim, Ingeborg M. Langohr, Mohammad Faisal, Margaret McNulty, Caitlin Thorn, Joomyeong Kim* Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA. Correspondence should be forwarded to: [email protected], 225-578-7692(ph), or 225-578-2597(fax) Running title: Function of Ezh2 in enteric neural crest cell development 1 bioRxiv preprint doi: https://doi.org/10.1101/265868; this version posted February 15, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract In the current study, we examined the role of Ezh2 as an epigenetic modifier for the enteric neural crest cell development through H3K27me3. Ezh2 conditional null mice were viable up to birth, but died within the first hour of life. In addition to craniofacial defects, Ezh2 conditional null mice displayed reduced number of ganglion cells in the enteric nervous system. RT-PCR and ChIP assays indicated aberrant up-regulation of Zic1, Pax3, and Sox10 and loss of H3K27me3 marks in the promoter regions of these genes in the myenteric plexus. Overall, these results suggest that Ezh2 is an important epigenetic modifier for the enteric neural crest cell development through repression of Zic1, Pax3, and Sox10.
    [Show full text]
  • Epigenetics in ENS Development and Hirschsprung Disease
    Developmental Biology 417 (2016) 209–216 Contents lists available at ScienceDirect Developmental Biology journal homepage: www.elsevier.com/locate/developmentalbiology Epigenetics in ENS development and Hirschsprung disease A. Torroglosa a,b, M.M. Alves c, R.M. Fernández a,b, G. Antiñolo a,b, R.M. Hofstra c,d, S. Borrego a,b,n a Department of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain b Centre for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain c Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands d Stem Cells and Regenerative Medicine, Birth Defects Research Centre UCL Institute of Child Health, London, UK article info abstract Article history: Hirschsprung disease (HSCR, OMIM 142623) is a neurocristopathy caused by a failure of the enteric Received 27 March 2016 nervous system (ENS) progenitors derived from neural crest cells (NCCs), to migrate, proliferate, differ- Received in revised form entiate or survive to and within the gastrointestinal tract, resulting in aganglionosis in the distal colon. 10 June 2016 The formation of the ENS is a complex process, which is regulated by a large range of molecules and Accepted 13 June 2016 signalling pathways involving both the NCCs and the intestinal environment. This tightly regulated Available online 16 June 2016 process needs correct regulation of the expression of ENS specific genes. Alterations in the expression of Keywords: these genes can have dramatic consequences. Enteric nervous system Several mechanisms that control the expression of genes have been described, such as DNA mod- Neural crest cells ification (epigenetic mechanisms), regulation of transcription (transcription factor, enhancers, repressors Hirschsprung disease and silencers), post-transcriptional regulation (3′UTR and miRNAs) and regulation of translation.
    [Show full text]
  • 14129 AEBP2 (D7C6X) Rabbit Mab
    Revision 1 C 0 2 - t AEBP2 (D7C6X) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] 9 Support: 877-678-TECH (8324) 2 1 Web: [email protected] 4 www.cellsignal.com 1 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP, ChIP, ChIP-seq H M R Mk Endogenous 70, 28 Rabbit IgG Q6ZN18 121536 Product Usage Information The zinc finger AE binding protein 2 (AEBP2) is another integral component of the PRC2 complex. Addition of AEBP2 to the PRC2 core complex (EZH2-EED-SUZ12) enhances For optimal ChIP and ChIP-seq results, use 20 μl of antibody and 10 μg of chromatin histone H3 Lys27 methyltransferase activity on nucleosomal substrates in vitro, which (approximately 4 x 106 cells) per IP. This antibody has been validated using SimpleChIP® may be mediated in part by three AEBP2 DNA-binding zinc finger domains (5,7). AEBP2- Enzymatic Chromatin IP Kits. mediated enhancement of enzymatic activity is greater on nucleosomal substrates that contain mono-ubiquitinated histone H2A Lys119, which suggests that AEBP2 may target Application Dilution PRC2 complexes in vivo through binding to DNA and mono-ubiquitinated histone H2A Lys119 (8). Western Blotting 1:1000 1. Boyer, L.A. et al. (2006) Nature 441, 349-53. Immunoprecipitation 1:50 2. Cao, R. et al. (2002) Science 298, 1039-43. Chromatin IP 1:25 3. Müller, J. et al. (2002) Cell 111, 197-208.
    [Show full text]
  • Functional Analysis of AEBP2, a PRC2 Polycomb Protein, Reveals A
    © 2016. Published by The Company of Biologists Ltd | Development (2016) 143, 2716-2723 doi:10.1242/dev.123935 STEM CELLS AND REGENERATION RESEARCH REPORT Functional analysis of AEBP2, a PRC2 Polycomb protein, reveals a Trithorax phenotype in embryonic development and in ESCs Anne Grijzenhout1, Jonathan Godwin1, Haruhiko Koseki2, Michal Ryszard Gdula1, Dorota Szumska3, Joanna F. McGouran4,*, Shoumo Bhattacharya3, Benedikt M. Kessler4, Neil Brockdorff1,‡ and Sarah Cooper1,‡ ABSTRACT There are two major Polycomb repressive complexes, PRC1 and The Polycomb repressive complexes PRC1 and PRC2 are key PRC2, which ubiquitylate histone H2A lysine 119 (H2AK119u1) mediators of heritable gene silencing in multicellular organisms. and methylate histone H3 lysine 27 (H3K27me1/2/3), respectively. Here, we characterise AEBP2, a known PRC2 co-factor which, Six major variant PRC1 complexes, defined by the presence of in vitro, has been shown to stimulate PRC2 activity. We show that different Polycomb group RING-finger subunits (Gao et al., 2012), AEBP2 localises specifically to PRC2 target loci, including the are present in mammals and are thought to have distinct roles in inactive X chromosome. Proteomic analysis confirms that AEBP2 targeting/maintenance of H2AK119u1 (Isono et al., 2013; associates exclusively with PRC2 complexes. However, analysis Blackledge et al., 2014). The PRC2 core complex consists of the of embryos homozygous for a targeted mutation of Aebp2 catalytic SET domain-containing subunit EZH1/2 and core subunits unexpectedly revealed a Trithorax phenotype, normally linked to EED, SUZ12 and RbAp46/48 (also known as RBBP7/4). antagonism of Polycomb function. Consistent with this, we observe Additionally, there are non-stoichiometric accessory factors that elevated levels of PRC2-mediated histone H3K27 methylation at associate with PRC2.
    [Show full text]
  • Functional Characterization of a Zinc Finger Protein AEBP2 Hana Kim Louisiana State University and Agricultural and Mechanical College, [email protected]
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2010 Functional characterization of a zinc finger protein AEBP2 Hana Kim Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Recommended Citation Kim, Hana, "Functional characterization of a zinc finger protein AEBP2" (2010). LSU Doctoral Dissertations. 3850. https://digitalcommons.lsu.edu/gradschool_dissertations/3850 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. ! ! ! ! !"#$%&'#()*$+(,($%-,&.(%&'#*'!*(*.&#$*!&#/-,*0,'%-&#* (-102* ! ! ! ! ! ! ! ! ! ! "!#$%%&'()($*+! ! ,-./$((&0!(*!(1&!2')0-)(&!3)4-5(6!*7!(1&! 8*-$%$)+)!,()(&!9+$:&'%$(6!)+0! ";'$4-5(-')5!)+0!<&41)+$4)5!=*55&;&!! $+!>)'($)5!7-57$55/&+(!*7!(1&!! '&?-$'&/&+(%!7*'!(1&!0&;'&&!*7!! #*4(*'!*7!@1$5*%*>16!! ! $+! ! A1&!#&>)'(/&+(!*7!B$*5*;$4)5!,4$&+4&%!! ! ! ! ! ! ! ! ! ! ! ! ! ! .6! Hana Kim B.M., Louisiana State University, 2006 December 2010 ACKNOWLEDGEMENTS I would like to thank Dr. Joomyeong Kim for being a great mentor and teaching me so much about science. I have learned that it takes patience and persistence to test the hypotheses you believe in. I thank Muhammad Ekram, and Dr. Michelle Thiaville for their ongoing support and suggestions, and previous lab members, Dr. Jennifer Huang, Dr. Chris Faulk, Dr. Jungha Choo and Keunsoo Kang, for their encouragement and help throughout my studies. I thank Dr. Jeongdo Kim and Dr. Sungryul Yu for teaching me many experimental techniques, and Dr.
    [Show full text]
  • Antibodies for Epigenetics and Gene Regulation Enabling Epigenetics Research
    antibodies for epigenetics and gene regulation Enabling Epigenetics Research 3 Chromatin Modifiers DNA Methylation Histones Transcription Regulation Highly Characterized Antibodies for Epigenetics and Gene Regulation At Active Motif, we are committed to providing the highest- polyclonal and AbFlex® recombinant antibodies are quality antibodies for studying epigenetics in the context validated for the applications you need – chromatin of histone and DNA modifications. Our antibodies are immunoprecipitation (ChIP), ChIP-Seq, Western blot, and manufactured in-house, and undergo rigorous development Immunofluorescence. and validation procedures to ensure their quality and To browse our complete list of antibodies and application performance. Our extensive, novel portfolio of monoclonal, data, please visit www.activemotif.com/abs. AbFlex® Recombinant Antibodies uniquely designed for multiple labeling methods AbFlex® antibodies are recombinant antibodies (rAbs) purification systems, and that have been generated using defined DNA sequences an avidin tag sequence to produce highly specific, reproducible antibodies. The for enzymatic biotin unique advantages of the AbFlex® antibody are its flexible conjugation using the biotin labeling and purification options. Each AbFlex® antibody ligase, BirA. contains a Sortase recognition motif (LPXTG) to covalently add fluorophores, enzymatic substrates (e.g., HRP), AbFlex is available for a peptides, DNA, drugs, or other labels to the antibody in range of Histone Markers, a directed and reproducible manner.
    [Show full text]
  • 39UTR Shortening Identifies High-Risk Cancers with Targeted Dysregulation
    OPEN 39UTR shortening identifies high-risk SUBJECT AREAS: cancers with targeted dysregulation of GENE REGULATORY NETWORKS the ceRNA network REGULATORY NETWORKS Li Li1*, Duolin Wang2*, Mengzhu Xue1*, Xianqiang Mi1, Yanchun Liang2 & Peng Wang1,3 Received 1 2 15 April 2014 Key Laboratory of Systems Biology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, College of Computer Science and Technology, Jilin University, 3School of Life Science and Technology, ShanghaiTech University. Accepted 3 June 2014 Competing endogenous RNA (ceRNA) interactions form a multilayered network that regulates gene Published expression in various biological pathways. Recent studies have demonstrated novel roles of ceRNA 23 June 2014 interactions in tumorigenesis, but the dynamics of the ceRNA network in cancer remain unexplored. Here, we examine ceRNA network dynamics in prostate cancer from the perspective of alternative cleavage and polyadenylation (APA) and reveal the principles of such changes. Analysis of exon array data revealed that both shortened and lengthened 39UTRs are abundant. Consensus clustering with APA data stratified Correspondence and cancers into groups with differing risks of biochemical relapse and revealed that a ceRNA subnetwork requests for materials enriched with cancer genes was specifically dysregulated in high-risk cancers. The novel connection between should be addressed to 39UTR shortening and ceRNA network dysregulation was supported by the unusually high number of P.W. (wangpeng@ microRNA response elements (MREs) shared by the dysregulated ceRNA interactions and the significantly sari.ac.cn) altered 39UTRs. The dysregulation followed a fundamental principle in that ceRNA interactions connecting genes that show opposite trends in expression change are preferentially dysregulated. This targeted dysregulation is responsible for the majority of the observed expression changes in genes with significant * These authors ceRNA dysregulation and represents a novel mechanism underlying aberrant oncogenic expression.
    [Show full text]
  • Supplemental Data
    Supplemental data Figure S1 ChIP-Seq analysis defines in vivo binding sites for Wt1 in the mouse genome (version mm10) relative to distance of transcriptional start sites. Mapping of the overlapping peaks from two independent ChIP-Seq experiments indicate that Wt1 works through both proximal and distal regulatory elements. Figure S2. Coomassie staining of SDS-PAGE gel with urine samples from inducible Wt1 podocyte-specific knock out mice. Mouse T846 with strong proteinuria served as a positive control. The first six mice showing slight proteinuria were used for the microarray experiment. 1 A B Figure S3 Neighboring motifs of Wt1 consensus sites in Wt1 up-regulated and down-regulated genes. (A) Neighboring motif of Wt1 consensus sites in Wt1 up-regulated genes indicating Sox 5 and Sox7 family binding motif. (B) Neighboring motif of Wt1 consensus sites in Wt1 down-regulated genes indicating Fox family binding motif (FoxP1, FoxP2, Foxj3, Foxj1, FoxK1 and Foxa2). 1 Figure S4. Venn diagram analysis of Wt1 up-regulated and Wt1 down-regulated genes along with podocytes enriched genes. The podocyte enriched gene list is from published data (fold change ≥ 2 compared to the rest of mouse glomeruli). 2 2 A 1.2 Nphs1 1 0.8 0.6 Nphs1 0.4 0.2 0 Control Wt1 mutant B 1.2 Sulf1 1 Sulf1 0.8 0.6 0.4 0.2 0 Control Wt1 mutant Figure S5 Wt1 positively regulates Nphs1 and Sulf1 in podocytes. (A, B) ChIP-Seq analysis on adult glomeruli identified Wt1 binding sites close to the transcription start sites of Nphs1 and Sulf1.
    [Show full text]
  • Identification of Genomic Targets of Krüppel-Like Factor 9 in Mouse Hippocampal
    Identification of Genomic Targets of Krüppel-like Factor 9 in Mouse Hippocampal Neurons: Evidence for a role in modulating peripheral circadian clocks by Joseph R. Knoedler A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Neuroscience) in the University of Michigan 2016 Doctoral Committee: Professor Robert J. Denver, Chair Professor Daniel Goldman Professor Diane Robins Professor Audrey Seasholtz Associate Professor Bing Ye ©Joseph R. Knoedler All Rights Reserved 2016 To my parents, who never once questioned my decision to become the other kind of doctor, And to Lucy, who has pushed me to be a better person from day one. ii Acknowledgements I have a huge number of people to thank for having made it to this point, so in no particular order: -I would like to thank my adviser, Dr. Robert J. Denver, for his guidance, encouragement, and patience over the last seven years; his mentorship has been indispensable for my growth as a scientist -I would also like to thank my committee members, Drs. Audrey Seasholtz, Dan Goldman, Diane Robins and Bing Ye, for their constructive feedback and their willingness to meet in a frequently cold, windowless room across campus from where they work -I am hugely indebted to Pia Bagamasbad and Yasuhiro Kyono for teaching me almost everything I know about molecular biology and bioinformatics, and to Arasakumar Subramani for his tireless work during the home stretch to my dissertation -I am grateful for the Neuroscience Program leadership and staff, in particular
    [Show full text]
  • JARID2 and AEBP2 Regulate PRC2 Activity in the Presence of H2A Ubiquitination Or Other Histone Modifications
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.20.049213; this version posted April 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. JARID2 and AEBP2 regulate PRC2 activity in the presence of H2A ubiquitination or other histone modifications Vignesh Kasinath1,*, Curtis Beck2, Paul Sauer1,3, Simon Poepsel4,5, Jennifer Kosmatka2, Marco Faini6, +, Dan Toso1, Ruedi Aebersold6,7, and Eva Nogales1,2,3,8,* 1 QB3 Institute, Department of Molecular and Cell Biology, University of California, Berkeley, California 94720, USA 2 Department of Molecular and Cellular Biology, University of California, Berkeley, California 94720, USA 3 Howard Hughes Medical Institute, University of California, Berkeley, California 94720, USA 4 Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany 5 Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, Cologne, Germany 6 Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093, Switzerland 7 Faculty of Science, University of Zurich, Zurich, Switzerland. 8 Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, USA * Corresponding authors: [email protected]; [email protected] + Present affiliation: Biomarkers, Bioinformatics and Omics & Pathology, Pharma Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.20.049213; this version posted April 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • JARID2 Is a Direct Target of the PAX3-FOXO1 Fusion Protein and Inhibits Myogenic Differentiation of Rhabdomyosarcoma Cells
    Oncogene (2014) 33, 1148–1157 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc ORIGINAL ARTICLE JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells ZS Walters1, B Villarejo-Balcells1, D Olmos1,2, TWS Buist1,3, E Missiaglia1,4, R Allen1, B Al-Lazikani3, MD Garrett5, J Blagg6 and J Shipley1 Rhabdomyosarcomas (RMS) are the most frequent soft-tissue sarcoma in children and characteristically show features of developing skeletal muscle. The alveolar subtype is frequently associated with a PAX3-FOXO1 fusion protein that is known to contribute to the undifferentiated myogenic phenotype of RMS cells. Histone methylation of lysine residues controls developmental processes in both normal and malignant cell contexts. Here we show that JARID2, which encodes a protein known to recruit various complexes with histone-methylating activity to their target genes, is significantly overexpressed in RMS with PAX3- FOXO1 compared with the fusion gene-negative RMS (t-test; Po0.0001). Multivariate analyses showed that higher JARID2 levels are also associated with metastases at diagnosis, independent of fusion gene status and RMS subtype (n ¼ 120; P ¼ 0.039). JARID2 levels were altered by silencing or overexpressing PAX3-FOXO1 in RMS cell lines with and without the fusion gene, respectively. Consistent with this, we demonstrated that JARID2 is a direct transcriptional target of the PAX3-FOXO1 fusion protein. Silencing JARID2 resulted in reduced cell proliferation coupled with myogenic differentiation, including increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representative of both the alveolar and embryonal subtypes.
    [Show full text]